We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
SUBSCRIBE: eNewsletter
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
Etanercept is a viable long-term treatment strategy for patients with psoriatic arthritis, and is both safe and effective when used in daily clinical practice, according to a new prospective long-term study.
Evaluating the cost of biologics for treating PsA: Adalimumab associated with highest costs, followed by Golimumab and Etanercept.
Psoriatic arthritis is associated with an additional increase in cardiovascular disease. One hypothesis shows that rheumatic diseases and atherosclerosis may be related due to an inflammatory mechanism.
Two studies published in leading medical journals show that secukinumab, a human monoclonal antibody used to treat psoriasis, could work in psoriatic arthritis.
Ultrasound and fluorescence optical imaging can detect inflammation in hand joints of rheumatoid arthritis and osteoarthritis patients.
T cell activator associated with psoriatic arthritis but not psoriasis.
Tofacitinib, an RA approved drug, shows promise for PsA.
Study shows that patients with psoriatic arthritis and cutaneous psoriasis could be good candidates for total hip replacement.
Distinguishing between different types of childhood arthritis is not always easy.
Psoriatic arthritis is a complex, understudied condition in older people who need more effective treatments.
